cancer – Page 6 – media

Lynparza tablets (ovarian cancer) given go-ahead by European regulators

With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
- Source: drugdu
- 749
- May 10, 2018
AstraZeneca cancer New Approvals pharma
CAR-T therapy could be available to NHS patients this year

NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
- Source: pharmatimes
- 5,098
- April 28, 2018
cancer NHS T cell therapy
Portable Cancer-Detecting Device Being Developed By Korean Startup

To diagnose cancer, doctors use a bunch of complex examinations like an MRI, a CT scan, a biopsy or a lengthy blood test. Because of the sophisticated machines and equipment needed for these techniques and procedures, they are only conducted in the hospital setting. One startup is about to change this with its portable cancer-detecting device.
- Source: International Business Times
- 1,962
- April 13, 2018
cancer medical device Researches
Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

The company, founded just a year ago, is developing novel glutamine antagonists that work as inhibitors of cancer metabolism, choking out tumors and their normal metabolic function.
- Source: Endpts
- 596
- April 3, 2018
cancer inhibitor Market Views metabolism
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
- Source: finance.yahoo
- 585
- March 22, 2018
ADCETRIS cancer FDA Hodgkin lymphoma New Approvals
ROCHE TO BUY FLATIRON HEALTH FOR $1.9 BN TO EXPAND CANCER CARE

Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion (1.35 billion pounds) to speed development of cancer medicines and support its efforts to price them based on how well they work.
- Source: Reuters
- 499
- March 15, 2018
cancer Market Views
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.
- Source: Xconomy
- 542
- March 5, 2018
cancer immunotherapy Series
Researchers develop new technology platform for cancer immunotherapy

Johns Hopkins researchers have invented a new class of immunotherapeutic agents that are more effective at harnessing the power of the immune system to fight cancer. Their approach results in significant inhibition of tumor growth, even against cancers which do not respond to existing immunotherapies used in the clinic. In collaboration with Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery, the team reports their results this week in Nature Communications.
- Source: immunotherapies
- 517
- February 27, 2018
cancer immunotherapies Researches
Gilead links with Sangamo in gene therapy alliance

Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
- Source: drugdu
- 545
- February 26, 2018
cancer engineered cell therapies Gilead Market Views
Primary care group uses population health IT to help prevent colon cancer

The national average colorectal screening rate is 39 percent but at Albany Area Primary Health Care it's 60 percent.
- Source: Healthcare IT News
- 511
- February 24, 2018
cancer health IT Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.